Epizyme Expands Clinical Collaboration to Study Tazemetostat and TECENTRIQ® Combination in NSCLC
June 26, 2017 06:30 ET
|
Epizyme, Inc.
Tazemetostat and Atezolizumab to be Evaluated as New Combination in Study of Non-Small Cell Lung Cancer as Part of Genentech’s MORPHEUS Cancer Immunotherapy Platform Further Expands Tazemetostat...
Epizyme Announces Tazemetostat Granted Orphan Drug Designation for the Treatment of Soft Tissue Sarcoma
June 21, 2017 06:30 ET
|
Epizyme, Inc.
CAMBRIDGE, Mass., June 21, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that the U.S. Food...
Epizyme Reports Positive Interim Data from Phase 2 Trial for Tazemetostat in Relapsed or Refractory Follicular Lymphoma and DLBCL Patients
June 14, 2017 08:30 ET
|
Epizyme, Inc.
Data Presented During Plenary Session at International Conference on Malignant Lymphoma Conference Call to be Held Today at 10:30 a.m. ET CAMBRIDGE, Mass., June 14, 2017 (GLOBE NEWSWIRE) --...
Epizyme Announces Path Toward Tazemetostat Registration in Epithelioid Sarcoma and Reports New Clinical Data to be Presented at ASCO
May 18, 2017 06:00 ET
|
Epizyme, Inc.
Path Toward Submission for Accelerated Approval Tazemetostat Demonstrates Clinically Meaningful Activity in Epithelioid Sarcoma; Interim Phase 2 Epithelioid Sarcoma and Synovial Sarcoma Data to be...
Epizyme Reports First Quarter 2017 Results and Provides Corporate Update
May 08, 2017 07:00 ET
|
Epizyme, Inc.
Interim Phase 2 Data of Tazemetostat in Molecularly Defined Solid Tumors and NHL to be Presented at Scientific Meetings in June Conference Call on Interim Solid Tumor Data to be Held on May 18, 2017 ...
Epizyme Earns $10 Million Milestone Payment from GlaxoSmithKline for Initiation of GLP Toxicology Studies with Novel Methyltransferase Inhibitor
May 04, 2017 06:30 ET
|
Epizyme, Inc.
CAMBRIDGE, Mass., May 04, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced it has earned a $10...
Epizyme Announces Tazemetostat Fast Track Designation for Follicular Lymphoma and Plenary Session on Phase 2 NHL Data at ICML
April 25, 2017 06:30 ET
|
Epizyme, Inc.
Interim Efficacy and Safety Data from Ongoing Phase 2 Study in Follicular Lymphoma and DLBCL Selected for Plenary Presentation at the International Conference on Malignant LymphomaManagement to Host...
Epizyme Announces Date of First Quarter 2017 Financial Results and Tazemetostat Data Presentations at ASCO
April 20, 2017 10:05 ET
|
Epizyme, Inc.
CAMBRIDGE, Mass., April 20, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that the Company...
Epizyme to Present New Preclinical Data on Tazemetostat and Epigenetic Target Identification Efforts at AACR Annual Meeting
March 29, 2017 06:30 ET
|
Epizyme, Inc.
CAMBRIDGE, Mass., March 29, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that new preclinical...
Epizyme Reports 2016 Financial Results and Provides 2017 Pipeline Goals
March 09, 2017 06:32 ET
|
Epizyme, Inc.
Data from Tazemetostat Phase 2 Programs in NHL and Molecularly Defined Solid Tumors Planned for Medical Meetings in Second Quarter Conference Call to Be Held Today at 8:30 a.m. Eastern Time ...